NCT04129502
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04129502
Title TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | TUR | SWE | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS


No variant requirements are available.